Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Proof-of-Concept Clinical Trial to Evaluate the Efficacy of Ketotifen and Indomethacin for Mild and Moderate COVID-19 in Adults
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Indometacin (Primary) ; Ketotifen (Primary)
- Indications COVID-19 respiratory infection
- Focus Proof of concept; Therapeutic Use
- Sponsors Sen Jam Pharmaceutical
- 24 Jun 2024 Status changed from recruiting to completed.
- 09 Jul 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 09 Jul 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2024.